Tycho Peterson
Stock Analyst at JP Morgan
(5.00)
# 1
Out of 4,857 analysts
131
Total ratings
66.3%
Success rate
270.3%
Average return
Main Sectors:
Stocks Rated by Tycho Peterson
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
A Agilent Technologies | Maintains: Overweight | $160 → $155 | $119.72 | +29.47% | 8 | May 29, 2025 | |
WGS GeneDx Holdings | Upgrades: Buy | $80 | $70.32 | +13.77% | 1 | May 9, 2025 | |
QDEL QuidelOrtho | Upgrades: Buy | $44 | $31.00 | +41.94% | 6 | May 8, 2025 | |
MTD Mettler-Toledo International | Upgrades: Hold | $1,200 → $1,100 | $1,192.98 | -7.79% | 8 | May 5, 2025 | |
DHR Danaher | Maintains: Overweight | $280 → $260 | $204.72 | +27.00% | 3 | Apr 22, 2025 | |
LH Labcorp Holdings | Maintains: Buy | $275 → $290 | $259.95 | +11.56% | 2 | Feb 6, 2025 | |
NEO NeoGenomics | Initiates: Buy | $22 | $7.83 | +180.97% | 1 | Dec 10, 2024 | |
DGX Quest Diagnostics | Assumes: Buy | $185 | $176.98 | +4.53% | 1 | Dec 10, 2024 | |
HOLX Hologic | Initiates: Hold | $85 | $64.58 | +31.62% | 7 | Dec 10, 2024 | |
QGEN Qiagen | Assumes: Buy | $43 → $56 | $46.72 | +19.05% | 5 | Dec 10, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $415 | $346.05 | +19.92% | 7 | Oct 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $35 | $35.15 | -0.43% | 3 | Aug 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $115 → $125 | $96.07 | +30.11% | 1 | Jul 29, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $24 | $10.78 | +122.63% | 7 | Jul 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $1.16 | +244.83% | 3 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $5 → $3 | $0.73 | +310.96% | 1 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $142 | $166.76 | -14.85% | 3 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $49.03 | -34.73% | 2 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $115 | $87.54 | +31.37% | 1 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underperform | $25 → $20 | $5.19 | +285.73% | 1 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $600 → $650 | $415.15 | +56.57% | 12 | Jun 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $26 → $9 | $12.06 | -25.34% | 1 | Sep 21, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.76 | - | 2 | Aug 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $12 | $2.19 | +447.95% | 2 | Aug 11, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $60 | $6.67 | +800.23% | 2 | Mar 2, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $2.99 | +669.23% | 1 | Aug 17, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $375 → $390 | $151.11 | +158.09% | 5 | May 28, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.33 | +1,629.32% | 1 | May 11, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $2.93 | +514.33% | 1 | Aug 10, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $188 → $200 | $522.41 | -61.72% | 9 | Jun 18, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $19.23 | +24.80% | 3 | Jun 1, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $65 → $45 | $16.10 | +179.50% | 5 | Mar 17, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $70 | $132.00 | -46.97% | 2 | Nov 2, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $120 | $158.83 | -24.45% | 1 | Feb 15, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.25 | - | 7 | Dec 13, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $39.72 | - | 5 | Nov 3, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $55 | $16.36 | +236.19% | 1 | Jul 19, 2016 |
Agilent Technologies
May 29, 2025
Maintains: Overweight
Price Target: $160 → $155
Current: $119.72
Upside: +29.47%
GeneDx Holdings
May 9, 2025
Upgrades: Buy
Price Target: $80
Current: $70.32
Upside: +13.77%
QuidelOrtho
May 8, 2025
Upgrades: Buy
Price Target: $44
Current: $31.00
Upside: +41.94%
Mettler-Toledo International
May 5, 2025
Upgrades: Hold
Price Target: $1,200 → $1,100
Current: $1,192.98
Upside: -7.79%
Danaher
Apr 22, 2025
Maintains: Overweight
Price Target: $280 → $260
Current: $204.72
Upside: +27.00%
Labcorp Holdings
Feb 6, 2025
Maintains: Buy
Price Target: $275 → $290
Current: $259.95
Upside: +11.56%
NeoGenomics
Dec 10, 2024
Initiates: Buy
Price Target: $22
Current: $7.83
Upside: +180.97%
Quest Diagnostics
Dec 10, 2024
Assumes: Buy
Price Target: $185
Current: $176.98
Upside: +4.53%
Hologic
Dec 10, 2024
Initiates: Hold
Price Target: $85
Current: $64.58
Upside: +31.62%
Qiagen
Dec 10, 2024
Assumes: Buy
Price Target: $43 → $56
Current: $46.72
Upside: +19.05%
Oct 8, 2024
Upgrades: Buy
Price Target: $355 → $415
Current: $346.05
Upside: +19.92%
Aug 5, 2024
Maintains: Underweight
Price Target: $28 → $35
Current: $35.15
Upside: -0.43%
Jul 29, 2024
Maintains: Hold
Price Target: $115 → $125
Current: $96.07
Upside: +30.11%
Jul 22, 2024
Upgrades: Buy
Price Target: $24
Current: $10.78
Upside: +122.63%
Jun 3, 2024
Initiates: Buy
Price Target: $4
Current: $1.16
Upside: +244.83%
Jun 3, 2024
Assumes: Hold
Price Target: $5 → $3
Current: $0.73
Upside: +310.96%
Jun 3, 2024
Initiates: Buy
Price Target: $142
Current: $166.76
Upside: -14.85%
Jun 3, 2024
Initiates: Buy
Price Target: $32
Current: $49.03
Upside: -34.73%
Jun 3, 2024
Assumes: Hold
Price Target: $115
Current: $87.54
Upside: +31.37%
Jun 3, 2024
Assumes: Underperform
Price Target: $25 → $20
Current: $5.19
Upside: +285.73%
Jun 3, 2024
Assumes: Buy
Price Target: $600 → $650
Current: $415.15
Upside: +56.57%
Sep 21, 2022
Downgrades: Underweight
Price Target: $26 → $9
Current: $12.06
Upside: -25.34%
Aug 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.76
Upside: -
Aug 11, 2022
Downgrades: Neutral
Price Target: $20 → $12
Current: $2.19
Upside: +447.95%
Mar 2, 2022
Maintains: Overweight
Price Target: $85 → $60
Current: $6.67
Upside: +800.23%
Aug 17, 2021
Initiates: Overweight
Price Target: $23
Current: $2.99
Upside: +669.23%
May 28, 2021
Maintains: Overweight
Price Target: $375 → $390
Current: $151.11
Upside: +158.09%
May 11, 2021
Initiates: Overweight
Price Target: $23
Current: $1.33
Upside: +1,629.32%
Aug 10, 2020
Initiates: Neutral
Price Target: $18
Current: $2.93
Upside: +514.33%
Jun 18, 2020
Maintains: Overweight
Price Target: $188 → $200
Current: $522.41
Upside: -61.72%
Jun 1, 2020
Maintains: Overweight
Price Target: $22 → $24
Current: $19.23
Upside: +24.80%
Mar 17, 2020
Maintains: Neutral
Price Target: $65 → $45
Current: $16.10
Upside: +179.50%
Nov 2, 2018
Maintains: Overweight
Price Target: $60 → $70
Current: $132.00
Upside: -46.97%
Feb 15, 2018
Maintains: Overweight
Price Target: $115 → $120
Current: $158.83
Upside: -24.45%
Dec 13, 2017
Downgrades: Underweight
Price Target: n/a
Current: $1.25
Upside: -
Nov 3, 2017
Downgrades: Neutral
Price Target: n/a
Current: $39.72
Upside: -
Jul 19, 2016
Initiates: Neutral
Price Target: $55
Current: $16.36
Upside: +236.19%